As reported in MedPage Today by Kate Kneisel, adding the oncolytic virus talimogene laherparepvec (T-VEC) to the checkpoint inhibitor ipilimumab (Yervoy) in advanced unresectable melanoma yielded no economic benefit over ipilimumab alone, when assessment was limited to objective response, researchers said. In progression-free survival (PFS) analyses, the cost of talimogene laherparepvec plus ipilimumab ($494,983) was almost quadruple that of ipilimumab monotherapy ($132,950), according to Ivo Abraham, PhD, of the University of Arizona in Tucson. See Ms. Kneiselā€™s article for the rest of the details.

Lead Research/Investigator

Ivo Abraham, PhD, of the University of Arizona

 

Source: MedPage Today

Pin It on Pinterest